M. Laird Forrest

8.2k total citations · 2 hit papers
109 papers, 6.5k citations indexed

About

M. Laird Forrest is a scholar working on Molecular Biology, Biomedical Engineering and Oncology. According to data from OpenAlex, M. Laird Forrest has authored 109 papers receiving a total of 6.5k indexed citations (citations by other indexed papers that have themselves been cited), including 51 papers in Molecular Biology, 26 papers in Biomedical Engineering and 24 papers in Oncology. Recurrent topics in M. Laird Forrest's work include RNA Interference and Gene Delivery (18 papers), Nanoparticle-Based Drug Delivery (17 papers) and Nanoplatforms for cancer theranostics (15 papers). M. Laird Forrest is often cited by papers focused on RNA Interference and Gene Delivery (18 papers), Nanoparticle-Based Drug Delivery (17 papers) and Nanoplatforms for cancer theranostics (15 papers). M. Laird Forrest collaborates with scholars based in United States, Canada and China. M. Laird Forrest's co-authors include Daniel W. Pack, Neal M. Davies, Yumei Xie, Cory Berkland, Glen S. Kwon, Shuang Cai, Pieter Stroeve, Sophie Laurent, Shahriar Sharifi and Morteza Mahmoudi and has published in prestigious journals such as Chemical Society Reviews, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

M. Laird Forrest

107 papers receiving 6.4k citations

Hit Papers

Toxicity of nanomaterials 2009 2026 2014 2020 2011 2009 250 500 750 1000

Peers

M. Laird Forrest
Yu Gao China
Rebecca M. Haley United States
Ping Yuan China
Marissa E. Wechsler United States
Jing Li China
Yu Gao China
M. Laird Forrest
Citations per year, relative to M. Laird Forrest M. Laird Forrest (= 1×) peers Yu Gao

Countries citing papers authored by M. Laird Forrest

Since Specialization
Citations

This map shows the geographic impact of M. Laird Forrest's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Laird Forrest with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Laird Forrest more than expected).

Fields of papers citing papers by M. Laird Forrest

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Laird Forrest. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Laird Forrest. The network helps show where M. Laird Forrest may publish in the future.

Co-authorship network of co-authors of M. Laird Forrest

This figure shows the co-authorship network connecting the top 25 collaborators of M. Laird Forrest. A scholar is included among the top collaborators of M. Laird Forrest based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Laird Forrest. M. Laird Forrest is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Yang, Xinmai, et al.. (2024). Investigating the potential of catheter‐assisted pulsed focused ultrasound ablation for atherosclerotic plaques. Medical Physics. 51(8). 5181–5189. 3 indexed citations
2.
Gong, Huan, et al.. (2024). Glatiramer Acetate Complexes CpG Oligodeoxynucleotides into Nanoparticles and Boosts Their TLR9-Driven Immunity. Molecular Pharmaceutics. 21(12). 6323–6338. 3 indexed citations
3.
Chakravarti, Aparna R., et al.. (2023). Design of a Tumor Binding GMCSF as Intratumoral Immunotherapy of Solid Tumors. Molecular Pharmaceutics. 20(4). 1975–1989. 6 indexed citations
4.
Huang, Aric, et al.. (2022). Glatiramer Acetate Complexed with CpG as Intratumoral Immunotherapy in Combination with Anti-PD-1. Molecular Pharmaceutics. 19(11). 4357–4369. 4 indexed citations
5.
Groer, Chad E., Ti Zhang, Shuang Cai, et al.. (2020). Intratumoral Cancer Chemotherapy with a Carrier-Based Immunogenic Cell-Death Eliciting Platinum (IV) Agent. Molecular Pharmaceutics. 17(11). 4334–4345. 23 indexed citations
6.
Donneys, Alexis, Qiuhong Yang, M. Laird Forrest, et al.. (2019). Implantable hyaluronic acid-deferoxamine conjugate prevents nonunions through stimulation of neovascularization. npj Regenerative Medicine. 4(1). 11–11. 30 indexed citations
7.
Fang, Pingping, et al.. (2018). Olaparib-induced Adaptive Response Is Disrupted by FOXM1 Targeting that Enhances Sensitivity to PARP Inhibition. Molecular Cancer Research. 16(6). 961–973. 34 indexed citations
8.
Xiong, Jian, Olivier Mozziconacci, Maulik K. Nariya, et al.. (2017). The Botanical Drug Substance Crofelemer as a Model System for Comparative Characterization of Complex Mixture Drugs. Journal of Pharmaceutical Sciences. 106(11). 3242–3256. 10 indexed citations
9.
Mellott, Adam J., Keerthana Devarajan, Heather Shinogle, et al.. (2015). Nonviral Reprogramming of Human Wharton's Jelly Cells Reveals Differences Between ATOH1 Homologues. Tissue Engineering Part A. 21(11-12). 1795–1809. 12 indexed citations
10.
Zhang, Ti, Huizhong Cui, Chia‐Yi Fang, et al.. (2015). Targeted Nanodiamonds as Phenotype-Specific Photoacoustic Contrast Agents for Breast Cancer. Nanomedicine. 10(4). 573–587. 33 indexed citations
11.
Mellott, Adam J., et al.. (2014). Improving Viability and Transfection Efficiency with Human Umbilical Cord Wharton's Jelly Cells Through Use of a ROCK Inhibitor. Cellular Reprogramming. 16(2). 91–97. 10 indexed citations
12.
Thati, Sharadvi, C.J. Kuehl, Brittany L. Hartwell, et al.. (2014). Routes of Administration and Dose Optimization of Soluble Antigen Arrays in Mice with Experimental Autoimmune Encephalomyelitis. Journal of Pharmaceutical Sciences. 104(2). 714–721. 18 indexed citations
13.
Devarajan, Keerthana, M. Laird Forrest, Michael S. Detamore, & Hinrich Staecker. (2013). Adenovector-Mediated Gene Delivery to Human Umbilical Cord Mesenchymal Stromal Cells Induces Inner Ear Cell Phenotype. Cellular Reprogramming. 15(1). 43–54. 17 indexed citations
14.
Thati, Sharadvi, et al.. (2013). Single-step grafting of aminooxy-peptides to hyaluronan: A simple approach to multifunctional therapeutics for experimental autoimmune encephalomyelitis. Journal of Controlled Release. 168(3). 334–340. 29 indexed citations
15.
Mohamed, Elham Abdelmonem, Yunqi Zhao, Mahasen Mohamed Meshali, et al.. (2012). Vorinostat with sustained exposure and high solubility in poly(ethylene glycol)‐b‐poly(dl‐lactic acid) micelle nanocarriers: Characterization and effects on pharmacokinetics in rat serum and urine. Journal of Pharmaceutical Sciences. 101(10). 3787–3798. 44 indexed citations
16.
Mellott, Adam J., M. Laird Forrest, & Michael S. Detamore. (2012). Physical Non-Viral Gene Delivery Methods for Tissue Engineering. Annals of Biomedical Engineering. 41(3). 446–468. 138 indexed citations
17.
Forrest, M. Laird, et al.. (2010). The Role of Lysosomes in Limiting Drug Toxicity in Mice. Journal of Pharmacology and Experimental Therapeutics. 333(1). 120–128. 25 indexed citations
18.
Vega‐Villa, Karina R., Jody K. Takemoto, Jaime A. Yáñez, et al.. (2008). Clinical toxicities of nanocarrier systems. Advanced Drug Delivery Reviews. 60(8). 929–938. 238 indexed citations
19.
Xiong, May P., Jaime A. Yáñez, Glen S. Kwon, Neal M. Davies, & M. Laird Forrest. (2008). A Cremophor-Free Formulation for Tanespimycin (17-AAG) Using PEO-b-PDLLA Micelles: Characterization and Pharmacokinetics in Rats. Journal of Pharmaceutical Sciences. 98(4). 1577–1586. 42 indexed citations
20.
Xiong, May P., Younsoo Bae, Shigeto Fukushima, et al.. (2007). pH‐Responsive Multi‐PEGylated Dual Cationic Nanoparticles Enable Charge Modulations for Safe Gene Delivery. ChemMedChem. 2(9). 1321–1327. 36 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026